Multiple myeloma (MM) is a tumor of monoclonal plasma cells, which produce a monoclonal antibody and expand predominantly in the bone marrow. Patients present with hypercalcemia, renal impairment, anemia, and/or bone disease. Only patients with symptomatic MM require therapy, whereas asymptomatic patients receive regular follow-up. Survival of patients with MM is very heterogeneous. The variety in outcome is explained by host factors as well as tumor-related characteristics reflecting biology of the MM clone and tumor burden. The identification of cytogenetic abnormalities by fluorescence in situ hybridization is currently the most important and widely available prognostic factor in MM.

Chromosomal abnormalities, Diagnostic workup, Multiple myeloma, Prognosis, Risk stratification
dx.doi.org/10.1016/j.hoc.2014.06.007, hdl.handle.net/1765/91811
Hematology / Oncology Clinics of North America
Erasmus MC: University Medical Center Rotterdam

van de Donk, N.W.C.J, & Sonneveld, P. (2014). Diagnosis and Risk Stratification in Multiple Myeloma. Hematology / Oncology Clinics of North America (Vol. 28, pp. 791–813). doi:10.1016/j.hoc.2014.06.007